Exablate Model 4000 Type 1.0 and 1.1 (Exablate Neuro; Exablate Prime)
Insightec · Decision date Mar 5, 2026
What did the FDA approve?
FDA records P150038/S042 as a supplement to PMA P150038, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Mar 5, 2026.
FDA approval order statement
Approval to add a third-party remote connection software used for installation and configuration management and to add the Siemens CimaX MRI to the list of compatible platforms.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Mar 5, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P150038/S042
- Regulatory pathway
- PMA supplement
- Applicant
- Insightec
- Product code
- POH
- Decision code
- APPR
- Decision date
- Mar 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: MR-guided focused ultrasound system.
For the original device and its historical approval scope, see PMA P150038. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150038 · Original PMA
EXABLATE
P150038/S042 received
Application receipt date recorded by FDA.
P150038/S043 · Related supplement
Exablate Model 4000 System
P150038/S042 · FDA decision
Real-Time Process
P150038/S044 · Related supplement
Exablate Model 4000 System
Timeline entries are records held by MedtechLedger for P150038. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150038
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EXABLATEP150038 | Insightec | PMA approval | Jul 11, 2016 | FDA |
Exablate Model 4000 SystemP150038/S043 | Insightec | PMA supplement | Jan 28, 2026 | FDA |
EXABLATEP150038/S041 | Insightec | PMA supplement | Mar 23, 2026 | FDA |
Exablate Model 4000 SystemP150038/S044 | Insightec | PMA supplement | Sep 16, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Insightec
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5 Nahum Heth St., Tirat Carmel, 39120
Sources and methodology
- Original FDA record: P150038/S042
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


